Triiodothyronine Treatment for Beta Cell Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapy methods for diabetes fail to produce mature, glucose-responsive insulin-secreting beta cells derived from stem or progenitor cells, as these cells are typically immature and do not secrete insulin in response to glucose, limiting their therapeutic value.
Innovation Solution
The method involves contacting an initial population of immature insulin-expressing beta cells with triiodothyronine (T3) or its analogs under specific conditions to induce maturation, resulting in an enriched population of mature, glucose-responsive insulin-secreting cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If stem cells or beta cell progenitors are differentiated into insulin-expressing cells, then insulin expression is achieved, but the cells remain immature and fail to secrete insulin in response to glucose
Solution Approach 1:
The patent applies parameter changes by treating immature beta cells with thyroid hormone (T3) to alter their developmental state. This hormonal treatment changes key parameters including MafA protein expression levels, cellular maturation status, and functional responsiveness to glucose, thereby transforming the cells from an immature non-secreting state to a mature secreting state capable of glucose-responsive insulin release
Solution Approach 2:
The patent employs preliminary action by pre-treating immature beta cells with thyroid hormone before transplantation or further use. This preliminary maturation treatment ensures that cells achieve the necessary functional maturity and glucose responsiveness prior to their therapeutic application, preventing the problem of immature cells failing to secrete insulin in vivo
2Productivity
If immature beta cells are used for cell therapy, then cell availability is increased, but therapeutic effectiveness is reduced due to lack of glucose responsiveness
Solution Approach 1:
The patent changes the functional parameters of produced beta cells through thyroid hormone treatment, transforming them from immature non-responsive cells to mature glucose-responsive cells. This parameter change approach maintains high cell production while ensuring therapeutic effectiveness by achieving functional maturity
Solution Approach 2:
The patent uses thyroid hormone as an intermediary substance to mediate the maturation process of beta cells. This intermediary agent facilitates the transition from immature to mature state without requiring complex procedural interventions, enabling effective cell therapy with readily available cell sources
Data Source
AI summary
Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject.